HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SLV 306

also an endothelin-converting enzyme-1 inhibitor; structure in first source

Also Known As:

SLV-306; SLV306; daglutril

Networked: 6 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - SLV 306: 6

Experts

1.	Azizi, Michel: 1 article (12/2013)
2.	Bobrie, Guillaume: 1 article (12/2013)
3.	Lorthioir, Aurélien: 1 article (12/2013)
4.	Monge, Matthieu: 1 article (12/2013)
5.	Benigni, Ariela: 1 article (09/2013)
6.	Bossi, Antonio: 1 article (09/2013)
7.	Daglutril in Diabetic Nephropathy Study Group: 1 article (09/2013)
8.	Gaspari, Flavio: 1 article (09/2013)
9.	Iliev, Ilian: 1 article (09/2013)
10.	Laurent, Stéphane: 1 article (09/2013)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 09/01/2013 - "Daglutril improved control of BP in hypertensive patients with type 2 diabetes and nephropathy and had an acceptable safety profile. " 09/01/2013 - "Daglutril for treatment of renal damage in hypertensive patients with type 2 diabetes: disappointment or hope?" 09/01/2013 - "Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial."
2.	Albuminuria 09/01/2013 - "Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial."
3.	Heart Failure 07/15/2004 - "Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure." 03/01/2003 - "SLV-306 is an orally active mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development by Solvay SA for the potential treatment of essential hypertension and congestive heart failure. "
4.	Proteinuria 11/01/2004 - "Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats."
5.	Diabetic Nephropathies (Diabetic Nephropathy) 12/01/2013 - "Daglutril is a dual neprylisin-endothelin converting enzyme inhibitor which was shown to decrease BP in patients with type 2 diabetic nephropathy. "

Related Drugs and Biologics

1.	Endothelin-Converting Enzymes
2.	Neprilysin (Neutral Endopeptidase)
3.	Albumins